Daiichi Sankyo Company, Limited (DSKYF)
Data as of October 25, 2026 · Drug Manufacturers - General
Stockbruh grade: Challenging 0/5 metrics rated Sunny
What does Daiichi Sankyo Company, Limited do?
Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products. The company boasts an extensive portfolio of therapeutics spanning numerous health conditions. In oncology, its offerings include trastuzumab deruxtecan, an innovative anti-HER2 antibody-drug conjugate for cancer treatment, alongside agents such as gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen for breast cancer. For chronic diseases, Daiichi Sankyo provides mirogabalin for pain management; treatments for type 2 diabetes mellitus like teneligliptin/canagliflozin and teneligliptin; and medications for hypercholesterolemia, including pravastatin and colesevelam (which also addresses type 2 diabetes).
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛅ Moderate | 5-year price performance |
| Profitability | ⛅ Moderate | Net margin & return on equity |
| Growth | ⛅ Moderate | Revenue & earnings trend |
| Earnings | ⛅ Moderate | EPS vs analyst expectations |
| Cash & Debt | ⛅ Moderate | Balance sheet strength |
| Price | $16.55 | Market Cap | — |
| Exchange | OTC | | |
Plain-English Analysis
What's it worth?
Performance has been moderate. Sign up free to see Stockbruh's full valuation analysis including price ratios and plain-English commentary.
How the business works
Daiichi Sankyo Company, Limited operates as a global pharmaceutical powerhouse, dedicated to the research, development, manufacturing, and worldwide commercialization of a wide array of medicinal products. The company boasts an extensive portfolio of therapeutics spanning numerous health conditions. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Growth is mixed — some positive signals, but not consistent. Sign up free for Stockbruh's full growth breakdown.
What's ahead?
Earnings are mixed. Sign up free for the full earnings picture including EPS history and analyst forecasts.